Heron Therapeutics, Inc. (HRTX)
Stock Price:
$15.53 USD
-0.51 (-3.18%)
Updated Jul 2, 2020 4:00 PM EDT - Market closed
Key Info
| Market Cap |
1.41B |
| Revenue (ttm) |
139.77M |
| Net Income (ttm) |
-193.32M |
| Shares Out |
90.64M |
| EPS (ttm) |
-2.28 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Jul 2, 2020 |
| Last Price |
$15.53 |
| Previous Close |
$16.04 |
| Change ($) |
-0.51 |
| Change (%) |
-3.18% |
| Day's Open |
16.26 |
| Day's Range |
15.32 - 16.44 |
| Day's Volume |
2,275,731 |
| 52-Week Range |
9.60 - 26.81 |
More Stats
| Market Cap |
1.41B |
| Enterprise Value |
1.08B |
| Earnings Date (est) |
Aug 10, 2020 |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
90.64M |
| Float |
84.49M |
| EPS (basic) |
-2.27 |
| EPS (diluted) |
-2.28 |
| FCF / Share |
-1.29 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
17.05M |
| Short Ratio |
16.36 |
| Short % of Float |
22.32% |
| Beta |
1.71 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
10.07 |
| PB Ratio |
4.96 |
| Revenue |
139.77M |
| Operating Income |
-198.73M |
| Net Income |
-193.32M |
| Free Cash Flow |
-116.45M |
| Net Cash |
330.95M |
| Net Cash / Share |
3.65 |
| Gross Margin |
-59.41% |
| Operating Margin |
-142.19% |
| Profit Margin |
-138.30% |
| FCF Margin |
-83.32% |
| ROA |
-27.16% |
| ROE |
-55.45% |
| ROIC |
-66.20% |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (10)
| Buy |
10 |
| Overweight |
0 |
| Hold |
0 |
| Underweight |
0 |
| Sell |
0 |
Price Target
$31.40*
(102.19% upside)
Low
19.0
Current: 15.53
High
70.0
Target: 31.40
*Average 12-month price target from 10 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 |
|---|
| Revenue | 146 | 77.47 | 30.77 | 1.28 | - | - | - | - | 0.65 | 1.30 |
| Revenue Growth | 88.41% | 151.81% | 2305.55% | - | - | - | - | - | -50.35% | - |
| Gross Profit | 84.35 | 49.96 | 26.18 | 1.24 | - | - | - | - | 0.65 | 1.30 |
| Operating Income | -211 | -184 | -195 | -171 | -96.81 | -75.48 | -54.46 | -23.83 | -11.06 | -9.93 |
| Net Income | -205 | -179 | -197 | -173 | -97.59 | -76.37 | -55.28 | -23.35 | -11.81 | -7.35 |
| Shares Outstanding | 81.78 | 73.19 | 54.04 | 37.93 | 33.08 | 26.57 | 16.16 | 12.22 | 6.01 | 1.98 |
| Earnings Per Share | -2.50 | -2.44 | -3.65 | -4.56 | -2.95 | -2.87 | -3.42 | -1.91 | -1.96 | -3.70 |
| Operating Cash Flow | -125 | -192 | -170 | -134 | -78.53 | -60.28 | -40.76 | -17.01 | -7.72 | -5.48 |
| Capital Expenditures | -7.15 | -9.15 | -2.48 | -3.14 | -0.85 | -1.44 | -1.69 | -0.97 | -0.51 | -0.08 |
| Free Cash Flow | -132 | -201 | -173 | -137 | -79.37 | -61.72 | -42.45 | -17.98 | -8.23 | -5.56 |
| Cash & Equivalents | 391 | 332 | 172 | 51.14 | 131 | 72.68 | 72.29 | 53.51 | 17.97 | 2.11 |
| Total Debt | 19.79 | 4.57 | 28.68 | 52.91 | 2.22 | 1.60 | 1.03 | 0.49 | 0.10 | - |
| Net Cash / Debt | 371 | 328 | 144 | -1.77 | 129 | 71.08 | 71.26 | 53.01 | 17.87 | 2.11 |
| Assets | 513 | 462 | 234 | 67.48 | 138 | 76.68 | 75.94 | 55.97 | 19.45 | 2.91 |
| Liabilities | 109 | 92.02 | 103 | 88.73 | 19.74 | 13.62 | 6.99 | 4.15 | 3.69 | 1.60 |
| Book Value | 404 | 370 | 131 | -21.25 | 118 | 63.06 | 68.95 | 51.82 | 15.75 | 1.32 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
Heron Therapeutics, Inc. |
| Country |
United States |
| Employees |
231 |
| CEO |
Barry D. Quart |
Stock Information
| Ticker Symbol |
HRTX |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
NASDAQ: HRTX |
| IPO Date |
August 26, 1987 |
Description
Heron Therapeutics, Inc., a biotechnology company, engages in developing treatments to address unmet medical needs. The company's product candidates utilize its proprietary Biochronomer drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron) extended-release injection for the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy, or anthracycline and cyclophosphamide combination chemotherapy regimens; and CINVANTI, an intravenous formulation of aprepitant, a substance P/neurokinin-1 receptor antagonist for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy, as well as nausea and vomiting associated with moderately emetogenic cancer chemotherapy. The company is also developing HTX-011, an investigational, dual-acting, and fixed-dose combination of the local anesthetic bupivacaine with a low dose of the nonsteroidal anti-inflammatory drug meloxicam that is in Phase III clinical trial for pain management; and HTX-034, a product candidate for postoperative pain management. The company was formerly known as A.P. Pharma, Inc. and changed its name to Heron Therapeutics, Inc. in January 2014. Heron Therapeutics, Inc. was founded in 1983 and is headquartered in San Diego, California.